A novel microparticulate vaccine for melanoma cancer using transdermal delivery
A novel microparticulate vaccine for melanoma cancer using transdermal delivery
复制标题
DOI：
10.3109/02652048.2011.559287
复制
发表时间：
2011-01-01
影响因子：
3.9
通讯作者：
D'Souza, Martin J.
中科院分区：
文献类型：
--
作者：
Bhowmik, Tuhin;D'Souza, Bernadette;D'Souza, Martin J.
在这项研究中，我们通过透皮途径配制了一种微粒黑色素瘤癌症疫苗。该疫苗是使用基于微针的Dermaroller（（R））递送的，该微针可用于美容目的。与皮下注射不同，使用微针给药是无痛的，并且通常可以增加许多化合物的渗透性，这些化合物的大小从小分子到蛋白质和微粒，通常不会穿透皮肤。疫苗微粒被抗原呈递细胞吸收，其在血清样品中显示出930 ug/mL的强IgG滴度水平。该制剂通过将抗原掺入大小范围为约0.63- 1.4 μ A μ m的白蛋白基质中作为合成佐剂而增加了疫苗的免疫原性。在8周的持续时间内，每14天给动物接种1次初免和4次加强剂量，然后用经皮接种后显示保护作用的活肿瘤细胞进行攻击。
In this study, we formulated a microparticulate melanoma cancer vaccine via the transdermal route. The vaccine was delivered using microneedle-based Dermaroller((R)) which is available for cosmetic purposes. Unlike subcutaneous injections, administration using microneedles is painless and in general can increase the permeability of many compounds ranging in size from small molecules to proteins and microparticles that do not normally penetrate the skin. The vaccine microparticles were taken up by the antigen presenting cells which demonstrated a strong IgG titre level of 930 ug/mL in serum samples. The formulation increased the immunogenicity of the vaccine by incorporating the antigen into an albumin matrix having a size range of around 0.63--1.4 mu A mu m which acted as a synthetic adjuvant. The animals were vaccinated with 1 prime and 4 booster doses administered every 14 days over 8 weeks duration, followed by challenge with live tumour cells which showed protection after transdermal vaccination.